scholarly journals Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
W. S. Cuello ◽  
T. A. T. Janes ◽  
J. M. Jessee ◽  
M. A. Venecek ◽  
M. E. Sawyer ◽  
...  
Keyword(s):  
Binding Site ◽  
Metabolic Pathways ◽  
Glutathione Transferase ◽  
Pbpk Modeling ◽  
Pathway Model ◽  
Site Model ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based ◽  
Uptake Data

Bromochloromethane (BCM) is a volatile compound and a by-product of disinfection of water by chlorination. Physiologically based pharmacokinetic (PBPK) models are used in risk assessment applications. An updated PBPK model for BCM is generated and applied to hypotheses testing calibrated using vapor uptake data. The two different metabolic hypotheses examined are (1) a two-pathway model using both CYP2E1 and glutathione transferase enzymes and (2) a two-binding site model where metabolism can occur on one enzyme, CYP2E1. Our computer simulations show that both hypotheses describe the experimental data in a similar manner. The two pathway results were comparable to previously reported values (Vmax=3.8 mg/hour,Km=0.35 mg/liter, andkGST=4.7 /hour). The two binding site results wereVmax⁡1=3.7 mg/hour,Km⁡1=0.3 mg/hour, CL2= 0.047 liter/hour. In addition, we explore the sensitivity of different parameters for each model using our obtained optimized values.

scholarly journals Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 813
Author(s):  
Yoo-Seong Jeong ◽  
Min-Soo Kim ◽  
Nora Lee ◽  
Areum Lee ◽  
Yoon-Jee Chae ◽  
...  
Keyword(s):  
Gastric Acid ◽  
Pbpk Model ◽  
Pbpk Modeling ◽  
Drug Candidate ◽  
Metabolite Formation ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based

Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacokinetic (PBPK) models predict drug interactions as pharmacokinetic profiles in biological matrices can be mechanistically simulated. Here, we propose an optimized and validated PBPK model for fexuprazan by integrating in vitro, in vivo, and in silico data. The extent of fexuprazan tissue distribution in humans was predicted using tissue-to-plasma partition coefficients in rats and the allometric relationships of fexuprazan distribution volumes (VSS) among preclinical species. Urinary fexuprazan excretion was minimal (0.29–2.02%), and this drug was eliminated primarily by the liver and metabolite formation. The fraction absorbed (Fa) of 0.761, estimated from the PBPK modeling, was consistent with the physicochemical properties of fexuprazan, including its in vitro solubility and permeability. The predicted oral bioavailability of fexuprazan (38.4–38.6%) was within the range of the preclinical datasets. The Cmax, AUClast, and time-concentration profiles predicted by the PBPK model established by the learning set were accurately predicted for the validation sets.

scholarly journals A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1191
Author(s):  
Tobias Kanacher ◽  
Andreas Lindauer ◽  
Enrica Mezzalana ◽  
Ingrid Michon ◽  
Celine Veau ◽  
...  
Keyword(s):  
San Francisco ◽  
Drug Exposure ◽  
Pbpk Modeling ◽  
Whole Body ◽  
Validation Dataset ◽  
Extrinsic Factors ◽  
Time Profiles ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based

Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However, there are only few verified, freely accessible, modifiable, and comprehensive drug–drug interaction (DDI) PBPK models. We developed a qualified whole-body PBPK DDI network for cytochrome P450 (CYP) CYP2C19 and CYP1A2 interactions. Template PBPK models were developed for interactions between fluvoxamine, S-mephenytoin, moclobemide, omeprazole, mexiletine, tizanidine, and ethinylestradiol as the perpetrators or victims. Predicted concentration–time profiles accurately described a validation dataset, including data from patients with genetic polymorphisms, demonstrating that the models characterized the CYP2C19 and CYP1A2 network over the whole range of DDI studies investigated. The models are provided on GitHub (GitHub Inc., San Francisco, CA, USA), expanding the library of publicly available qualified whole-body PBPK models for DDI predictions, and they are thereby available to support potential recommendations for dose adaptations, support labeling, inform the design of clinical DDI trials, and potentially waive those.

scholarly journals Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 578 ◽  
Author(s):  
Lukas Kovar ◽  
Christina Schräpel ◽  
Dominik Selzer ◽  
Yvonne Kohl ◽  
Robert Bals ◽  
...  
Keyword(s):  
Drug Exposure ◽  
Geometric Mean ◽  
Pbpk Modeling ◽  
Preterm Neonates ◽  
Pharmacokinetic Studies ◽  
Acceptance Criterion ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Age Related ◽  
Physiologically Based

Buprenorphine plays a crucial role in the therapeutic management of pain in adults, adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of buprenorphine in children, particularly neonates, are available as conducting clinical trials in this population is especially challenging. Physiologically-based pharmacokinetic (PBPK) modeling allows the prediction of drug exposure in pediatrics based on age-related physiological differences. The aim of this study was to predict the pharmacokinetics of buprenorphine in pediatrics with PBPK modeling. Moreover, the drug-drug interaction (DDI) potential of buprenorphine with CYP3A4 and P-glycoprotein perpetrator drugs should be elucidated. A PBPK model of buprenorphine and norbuprenorphine in adults has been developed and scaled to children and preterm neonates, accounting for age-related changes. One-hundred-percent of the predicted AUClast values in adults (geometric mean fold error (GMFE): 1.22), 90% of individual AUClast predictions in children (GMFE: 1.54) and 75% in preterm neonates (GMFE: 1.57) met the 2-fold acceptance criterion. Moreover, the adult model was used to simulate DDI scenarios with clarithromycin, itraconazole and rifampicin. We demonstrate the applicability of scaling adult PBPK models to pediatrics for the prediction of individual plasma profiles. The novel PBPK models could be helpful to further investigate buprenorphine pharmacokinetics in various populations, particularly pediatric subgroups.

Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures

2020 ◽  
Author(s):  
Teerachat Saeheng ◽  
Juntra Karbwang ◽  
Rajith Kumar Reddy Rajoli ◽  
Marco Siccardi ◽  
Kesara Na-Bangchang
Keyword(s):  
Cerebral Malaria ◽  
Dose Regimen ◽  
Optimal Dose ◽  
Model Verification ◽  
Pbpk Modeling ◽  
Whole Body ◽  
Loading Dose ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based

Abstract Background: Cerebral malaria is a fatal disease. Patients with cerebral malaria are at risk of seizure development, therefore, the co-administration of antimalarial and antiepileptic drugs are needed. Quinine and phenobarbital are standard drugs for the treatment of cerebral malaria with seizures. However, there is no information on the optimal dosage regimens of both drugs when used concomitantly.T he study applied physiologically-based pharmacokinetic (PBPK) modeling for prediction of the optimal dose regimens of quinine and phenobarbital when co-administered in patients with cerebral malaria and concurrent seizures who carry wild type and polymorphic cytochrome P450 (CYP450) 2C9/2C19. Methods: The whole-body PBPK models for quinine and phenobarbital were constructed based on the previously published information using Simbiology®. One hundred virtual population were simulated. Four published articles were used for model verification. Sensitivity analysis was carried out to determine the effect of the changes in model parameters on AUC0–72h. Simulation of optimal dose regimens was based on standard drug-drug interactions (DDIs), and actual clinical use study approaches. Results: Dose adjustment of the standard regimen of phenobarbital is not required when co-administered with quinine. The proposed optimal dose regimen for quinine, when co-administered with phenobarbital for patients with a single or continuous seizure in all malaria-endemic areas regardless of CYP2C9/CYP2C19 genotypes, is a loading dose of 1,500 mg IV infusion over 8 hours, followed by 1,200 mg infusion over 8 hours given three times daily, or multiple doses of 1,400 mg IV infusion over 8 hours, given three times daily. In areas with quinine resistance, the dose regimen should be increased as a loading dose of 2,000 mg IV infusion over 8 hours, followed by 1,750 mg infusion over 8 hours given three times daily.Conclusion: The developed PBPK models are reliable, and successfully predicted the optimal doses regimens of quinine-phenobarbital co-administration with no requirement of CYP2C9/CYP2C19 genotyping.

scholarly journals The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development

2021 ◽  
Vol 71 (4) ◽  
pp. 318-335
Author(s):  
Sandra Cvijić ◽  
Jelisaveta Ignjatović ◽  
Jelena Parojčić ◽  
Svetlana Ibrić
Keyword(s):  
In Silico ◽  
Pbpk Modeling ◽  
Formulation Development ◽  
Modeling Tools ◽  
Simulation Tools ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based ◽  
Computer Based ◽  
Application Fields

Computer-based (in silico) modeling & simulation tools have been embraced in different fields of pharmaceutics for a variety of applications. Among these, physiologically-based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) emerged as a particularly useful tool in formulation development. PBPK/PBBM facilitated strategies have been increasingly evaluated over the past few years, as demonstrated by several reports from the pharmaceutical industry, and a number of research and review papers on this subject. Also, the leading regulatory authorities have recently issued guidance on the use of PBPK modeling in formulation design. In silico PBPK models can comprise different dosing routes (oral, intraoral, parenteral, inhalation, ocular, dermal etc.), although the majority of published examples refer to modeling of oral drugs performance. In order to facilitate the use of PBPK modeling tools, a couple of companies have launched commercially available software such as GastroPlus™, Simcyp™ PBPK Simulator and PK-Sim®. This paper highlights various application fields of PBPK/PBBM modeling, along with the basic principles, advantages and limitations of this approach, and provides relevant examples to demonstrate the practical utility of modeling & simulation tools in different stages of formulation development.

scholarly journals Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Feras Khalil ◽  
Stephanie Läer
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Age Groups ◽  
Modeling Technique ◽  
Pbpk Modeling ◽  
Pediatric Drug ◽  
Pediatric Drug Development ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based

The concept of physiologically based pharmacokinetic (PBPK) modeling was introduced years ago, but it has not been practiced significantly. However, interest in and implementation of this modeling technique have grown, as evidenced by the increased number of publications in this field. This paper demonstrates briefly the methodology, applications, and limitations of PBPK modeling with special attention given to discuss the use of PBPK models in pediatric drug development and some examples described in detail. Although PBPK models do have some limitations, the potential benefit from PBPK modeling technique is huge. PBPK models can be applied to investigate drug pharmacokinetics under different physiological and pathological conditions or in different age groups, to support decision-making during drug discovery, to provide, perhaps most important, data that can save time and resources, especially in early drug development phases and in pediatric clinical trials, and potentially to help clinical trials become more “confirmatory” rather than “exploratory”.

Evaluating parameter availability for physiologically based pharmacokinetic (PBPK) modeling of perfluorooctanoic acid (PFOA) in zebrafish

2018 ◽  
Vol 20 (1) ◽  
pp. 105-119 ◽  
Author(s):  
Manoochehr Khazaee ◽  
Carla A. Ng
Keyword(s):  
Perfluorooctanoic Acid ◽  
Pbpk Modeling ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Physiologically Based

Physiologically based pharmacokinetic (PBPK) models are considered useful tools to describe the absorption, distribution, metabolism and excretion of xenobiotics.

scholarly journals Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 908
Author(s):  
Lukas Kovar ◽  
Andreas Weber ◽  
Michael Zemlin ◽  
Yvonne Kohl ◽  
Robert Bals ◽  
...  
Keyword(s):  
Pbpk Model ◽  
Peak Plasma ◽  
Plasma Concentrations ◽  
Pbpk Modeling ◽  
Pharmacokinetic Studies ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Age Related ◽  
Physiologically Based ◽  
Pediatric Populations

Fentanyl is widely used for analgesia, sedation, and anesthesia both in adult and pediatric populations. Yet, only few pharmacokinetic studies of fentanyl in pediatrics exist as conducting clinical trials in this population is especially challenging. Physiologically-based pharmacokinetic (PBPK) modeling is a mechanistic approach to explore drug pharmacokinetics and allows extrapolation from adult to pediatric populations based on age-related physiological differences. The aim of this study was to develop a PBPK model of fentanyl and norfentanyl for both adult and pediatric populations. The adult PBPK model was established in PK-Sim® using data from 16 clinical studies and was scaled to several pediatric subpopulations. ~93% of the predicted AUClast values in adults and ~88% in pediatrics were within 2-fold of the corresponding value observed. The adult PBPK model predicted a fraction of fentanyl dose metabolized to norfentanyl of ~33% and a fraction excreted in urine of ~7%. In addition, the pediatric PBPK model was used to simulate differences in peak plasma concentrations after bolus injections and short infusions. The novel PBPK models could be helpful to further investigate fentanyl pharmacokinetics in both adult and pediatric populations.

A Physiologically Based Pharmacokinetic Model of Parathion Based on Chemical-Specific Parameters Determined In Vitro

1990 ◽  
Vol 9 (6) ◽  
pp. 611-619 ◽  
Author(s):  
Lester G. Sultatos
Keyword(s):  
Pbpk Model ◽  
Equilibrium Dialysis ◽  
Distribution Coefficients ◽  
Kinetic Constants ◽  
Pbpk Modeling ◽  
Pbpk Models ◽  
Physiologically Based Pharmacokinetic ◽  
Hepatic Extraction Ratio ◽  
Physiologically Based

Physiologically based pharmacokinetic (PBPK) modeling is an approach that has been used to predict successfully the pharmacokinetic disposition of numerous foreign chemicals. The accuracy of a PBPK model is dependent on the reliability of estimates of tissue/blood distribution coefficients (Kp) and appropriate kinetic constants descriptive of the elimination of the chemical under consideration. The present study evaluates the validity of the use of Kp values and kinetic constants determined in vitro for use in a PBPK model for the organothiophosphorus insecticide parathion. Kps were determined by equilibrium dialysis, whereas Vmaxs and Kms descriptive of the biotransformation of parathion were calculated from values determined previously in this laboratory. Using these kinetic constants to calculate a hepatic extraction ratio of parathion in the mouse yielded a value identical to that observed with mouse liver perfusions in situ performed previously in this laboratory. Use of Kp values and kinetic constants determined in vitro in a PBPK model accurately simulated levels of parathion in brain, lungs, blood, and liver up to 3 h after intravenous administration of this insecticide. This study demonstrates that chemical-specific parameters determined entirely in vitro can be used to construct accurate PBPK models.

Sign in / Sign up

Export Citation Format

Share Document